RT Journal Article
SR Electronic
T1 Real-world comparative effectiveness of a third dose of mRNA-1273 versus BNT162b2 among adults aged ≥65 years in the United States
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.11.03.23298054
DO 10.1101/2023.11.03.23298054
A1 Kirk, Brenna
A1 Bush, Chris
A1 Toyip, Astra
A1 Mues, Katherine E.
A1 Beck, Ekkehard
A1 Li, Linwei
A1 St. Laurent, Samantha
A1 Georgieva, Mihaela
A1 Marks, Morgan A.
A1 Sun, Tianyu
A1 Esposito, Daina B.
A1 Martin, David
A1 Van de Velde, Nicolas
YR 2023
UL http://medrxiv.org/content/early/2023/11/04/2023.11.03.23298054.abstract
AB Introduction To compare the real-world effectiveness of a third dose of mRNA-1273 versus a third dose of BNT162b2 against breakthrough COVID-19 hospitalizations among adults age ≥65 years who completed a primary series of an mRNA-based COVID-19 vaccine (regardless of which primary series was received).Materials and methods This observational comparative vaccine effectiveness (VE) study was conducted using administrative claims data from the US HealthVerity database (September 22, 2021, to August 31, 2022). A third dose of mRNA-1273 versus BNT162b2 was assessed for preventing COVID-19 hospitalizations and medically attended COVID-19 among adults ≥65 years. Inverse probability of treatment weighting was applied to balance baseline characteristics between vaccine groups. Incidence rates from patient-level data and hazard ratios (HRs) with 95% confidence intervals (CIs) using weighted Cox proportional hazards models were calculated to estimate relative VE for each outcome.Results Overall, 94,587 and 92,377 individuals received a third dose of mRNA-1273 and BNT162b2, respectively. Among the weighted population, the median age was 69 years (interquartile range, 66-74), 53% were female, and 46% were commercially insured. COVID-19 hospitalization rates per 1000 person-years (PYs) were 5.61 (95% CI, 5.13-6.09) for mRNA-1273 and 7.06 (95% CI, 6.54-7.57) for BNT162b2 (HR, 0.82; 0.69-0.98). Medically attended COVID-19 rates per 1000 PYs (95% CI) were 95.05 (95% CI, 93.03-97.06) for mRNA-1273 and 106.55 (95% CI, 104.53-108.57) for BNT162b2 (HR, 0.93; 0.89-0.98).Conclusions Results from this observational comparative VE database study provide evidence that among older adults, a third dose of mRNA-1273 was more effective in preventing breakthrough COVID-19 hospitalization and medically attended COVID-19 infection compared with a third dose of BNT162b2.Competing Interest StatementEB, LL, SSL, MG, MAM, TS, DBE, DM, and NV are employees of Moderna, Inc., and hold stock/stock options in the company. BK, CB, AT, and KEM are employees of Aetion, Inc., which has been contracted by Moderna, Inc., for the conduct of the present study. BK, CB, and KEM are stock option holders in Aetion, Inc.Funding StatementThis work was supported by Moderna, Inc.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was fully approved by the WCG Institutional Review Board (#20231679)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesIndividual-level data reported in this study are not publicly shared. Upon request, and subject to review, Aetion, Inc., may provide the deidentified aggregate-level data that support the findings of this study. Deidentified data (including participant data as applicable) may be shared upon approval of an analysis proposal and a signed data access agreement.